The UK government has confirmed that CE-marked medical devices and in vitro diagnostic devices (IVDs) will continue to be accepted in Great Britain on a long-term basis, removing the prospect of a separate approval step for products already cleared for the European market.
The decision covers technologies that patients and the NHS rely on, from insulin pumps and replacement joints to diagnostic tests and surgical equipment, and is intended to help keep supply stable.
Consultation and rationale
The announcement follows a public consultation that ran from 16 February 2026 to 10 April 2026 and drew more than 1,000 responses from patients, healthcare organisations, industry and other respondents.
According to the government, continued recognition avoids duplicated assessment for manufacturers and helps maintain uninterrupted access to medical technologies. More than 90% of medical devices currently registered for use in Great Britain carry a CE mark, meaning they have been assessed and approved for the European market, and that approval has been recognised as providing access to the Great British market.
UKCA route continues
The CE route sits alongside UKCA marking, which continues to operate as the domestic approval pathway for devices placed on the market in Great Britain. Guidance on placing UKCA or CE-marked products on the market in Great Britain is available to manufacturers.
